Paediatric preclinical models (PDX) to study novel therapeutics
Research type
Research Study
Full title
A comprehensive paediatric preclinical package of care platform to enable clinical molecule development for children and young adults with cancer.
IRAS ID
243123
Contact name
Louis Chesler
Contact email
Sponsor organisation
The Institute of Cancer Research
Clinicaltrials.gov Identifier
116064, IMI2 Grant Reference Number
Duration of Study in the UK
4 years, 11 months, 30 days
Research summary
Although there is a general trend of increasing survival for children diagnosed with cancer, it remains the most frequent cause of death in childhood. Malignant diseases in childhood and adolescence can be cured in up to 75% of cases with modern treatment protocols, but relapses and the progression of high-risk diseases still remains an enormous clinical challenge. There are hardly any suitable therapy options for children suffering a relapse of a malignant tumour. Preclinical drug testing tailored to the respective tumour entity sometimes fails because (a) the molecular genetic data for solid tumours of children with relapse and thus also the knowledge about the tumour evolution is very low and (b) especially for high risk entities there are insufficient well-characterized mouse models and thus little corresponding predictive preclinical drug testing. This European “Innovative Therapies for Children with Cancer“ (ITCC) research programme, of which The Institute of Cancer Research / The Royal Marsden is a partner, aims to create clinically and biologically relevant orthotopic mouse models of childhood cancers, which will lead to a more successful testing system for pre-clinical drug development and mechanistic studies.
REC name
London - Camden & Kings Cross Research Ethics Committee
REC reference
18/LO/1949
Date of REC Opinion
29 Nov 2018
REC opinion
Favourable Opinion